Genetic Engineering of Surrogate <i>β</i>Cells for Treatment of Type 1 Diabetes Mellitus

• 作者: Andrew M. Handorf Hans W. Sollinger Tausif Alam
• 来源期刊: 糖尿病(英文)
• 学科: 医学
• 关键词: Gene THERAPY Cell THERAPY INSULIN Type 1 Diabetes MELLITUS HEPATOCYTES
• 年，卷（期）: tnbyw_2015,（4）
• 页码范围: 295-312
• 页数: 18页
• 分类号: R73

摘要

Type 1 diabetes mellitus (T1DM) is an autoimmune disease resulting from the destruction of the insulin-producing β cells of the pancreas. While treatment options like daily insulin injections or transplantation of whole-pancreas exist, they are associated with significant drawbacks. As a result, there has been great interest in engineering surrogate β cells, both ex vivo and in situ, to replace the function of those cells lost during the progression of the disease. However, the β cell is highly specialized and extraordinarily adept at synthesizing and rapidly secreting the appropriate amount of insulin in response to even small increases in blood glucose levels. Thus, genetic engineering of the “perfect” β cell may prove impossible. In this review, we will detail the features of β cells that make them so proficient at regulating blood glucose and highlight the key features that absolutely must be met by surrogate β cells if they are to be suitable for treatment of T1DM. Then, we will summarize the current approaches used to genetically engineer surrogate β cells, including the overexpression of β cell-specific transcription factors and insulin gene therapy. Along the way, we will discuss the advantages and disadvantages of each approach and review important studies in the field. Lastly, we will discuss important future directions necessary to genetically engineer surrogate β cells with the potential to treat T1DM.